Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TNXP Revenue Growth
TNXP Revenue Analysis (2013–2024)
As of May 8, 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) generated trailing twelve-month (TTM) revenue of $10.3 million, reflecting strong growth of +16.6% year-over-year. The most recent quarter (Q3 2025) recorded $3.3 million in revenue, up 64.7% sequentially.
Looking at the longer-term picture, TNXP's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $10.1 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including AXSM (+63.9% YoY), INVA (+13.6% YoY), and SUPN (+16.3% YoY), TNXP has underperformed the peer group in terms of revenue growth. Compare TNXP vs AXSM →
TNXP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TNXPCurrent | $10M | +16.6% | - | -1354.3% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% |
TNXP Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $10.1M | +29.9% | $2.3M | 23.1% | $-136,701,000 | -1354.3% |
| 2023 | $7.8M | - | $3.0M | 39.0% | $-118,380,000 | -1523.9% |
| 2022 | $0 | - | $0 | - | $-112,091,000 | - |
| 2021 | $0 | - | $0 | - | $-92,312,000 | - |
| 2020 | $0 | - | $-27,000 | - | $-50,511,000 | - |
| 2019 | $0 | - | $0 | - | $-28,828,000 | - |
| 2018 | $0 | - | $-26,322,000 | - | $-26,322,000 | - |
| 2017 | $0 | - | $-21,291,000 | - | $-21,291,000 | - |
| 2016 | $0 | - | $-38,969,000 | - | $-38,969,000 | - |
| 2015 | $0 | - | $-48,162,000 | - | $-48,162,000 | - |
See TNXP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNXP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNXP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTNXP — Frequently Asked Questions
Quick answers to the most common questions about buying TNXP stock.
Is TNXP's revenue growth accelerating or slowing?
TNXP revenue is accelerating at +16.6% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $10M. Growth momentum has increased versus prior periods.
What is TNXP's long-term revenue growth rate?
Tonix Pharmaceuticals Holding Corp.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +16.6% is above this long-term average.
How is TNXP's revenue distributed by segment?
TNXP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.